Trial Profile
A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS JAVELIN BRCA/ATM
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Talazoparib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms Javelin BRCA/ATM
- Sponsors Pfizer
- 04 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 12 Mar 2023 This study has been completed in Netherland (Global end date: 2023-02-03), According to European Clinical Trials Database record record.
- 18 Jan 2023 Planned End Date changed from 29 Dec 2022 to 8 Feb 2023.